58-39-9 | 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol

Packsize	Purity	Availability	Price	Discounted Price
250mg	98%	in stock	$15.00	$10.00
1g	98%	in stock	$16.00	$11.00
5g	98%	in stock	$22.00	$15.00
25g	98%	in stock	$60.00	$42.00
100g	98%	in stock	$228.00	$159.00

Description

• Catalog Number: AG64736
• Chemical Name: 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol
• CAS Number: 58-39-9
• Molecular Formula: C21H26ClN3OS
• Molecular Weight: 403.96864000000005
• MDL Number: MFCD00056798
• SMILES: OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2

Computed Properties

• Complexity: 463
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6
• XLogP3: 4.2

Literature

• Why are most phospholipidosis inducers also hERG blockers?

  Archives of toxicology 20171201

• Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.

  Antimicrobial agents and chemotherapy 20140601

• Antitubercular pharmacodynamics of phenothiazines.

  The Journal of antimicrobial chemotherapy 20130401

• Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.

  Journal of psychopharmacology (Oxford, England) 20120901

• Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.

  The Journal of clinical psychiatry 20120901

• Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility.

  Schizophrenia research 20120501

• Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.

  Clinical schizophrenia & related psychoses 20120401

• Prevalence of neuroleptic-induced restless legs syndrome in patients taking neuroleptic drugs.

  Journal of the neurological sciences 20120315

• Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.

  Medical science monitor : international medical journal of experimental and clinical research 20120101

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study.

  Clinical schizophrenia & related psychoses 20111001

• Alternative methods for testing treatment effects on the basis of multiple outcomes: simulation and case study.

  Statistics in medicine 20110720

• Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.

  Journal of medicinal chemistry 20110714

• Periodic catatonia.

  Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20110501

• Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

  The Journal of clinical psychiatry 20110301

• Post-operative nausea and vomiting prevention with perphenazine: long overdue.

  European journal of anaesthesiology 20110201

• Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.

  Molecular psychiatry 20110101

• Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

  The Journal of clinical psychiatry 20110101

• Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits.

  The Journal of pharmacy and pharmacology 20110101

• Electroconvulsive therapy for the treatment of refractory mania.

  Journal of psychiatric practice 20110101

• Investigation of neuropsychopharmacological effects of a polyherbal formulation on the learning and memory process in rats.

  Journal of young pharmacists : JYP 20110101

• Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.

  Neuro endocrinology letters 20110101

• Impaired cerebellar functional connectivity in schizophrenia patients and their healthy siblings.

  Frontiers in psychiatry 20110101

• Efficacy of perphenazine to prevent postoperative nausea and vomiting: a quantitative systematic review.

  European journal of anaesthesiology 20101201

• Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.

  Assay and drug development technologies 20101201

• Schizophrenia: The drug deadlock.

  Nature 20101111

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Perphenazine solid dispersions for orally fast-disintegrating tablets: physical stability and formulation.

  Drug development and industrial pharmacy 20100501

• The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs.

  Pharmacopsychiatry 20100501

• Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.

  Toxicology 20100411

• Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.

  Schizophrenia research 20100301

• A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.

  Proceedings of the National Academy of Sciences of the United States of America 20100223

• Effect of perphenazine enanthate on open-field test behaviour and stress-induced hyperthermia in domestic sheep.

  Pharmacology, biochemistry, and behavior 20100101

• BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.

  Current opinion in investigational drugs (London, England : 2000) 20100101

• An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.

  Clinical neuropharmacology 20100101

• Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats.

  Pharmacology, biochemistry, and behavior 20091201

• BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20091201

• The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.

  Schizophrenia research 20091101

• Clinical trials design lessons from the CATIE study.

  The American journal of psychiatry 20091101

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.

  Bioorganic & medicinal chemistry letters 20090901

• 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

  Lancet (London, England) 20090822

• Effect of antipsychotic drug perphenazine on fast sodium current and transient outward potassium current in rat ventricular myocytes.

  Naunyn-Schmiedeberg's archives of pharmacology 20090801

• Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.

  The Journal of clinical psychiatry 20090421

• Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.

  Bioorganic & medicinal chemistry 20090315

• Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics.

  Early intervention in psychiatry 20090201

• BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20090101

• Results of phase 3 of the CATIE schizophrenia trial.

  Schizophrenia research 20090101

• Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.

  Archives of toxicology 20081201

• Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms.

  Bipolar disorders 20081201

• Hiccups and dopamine.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081115

• Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.

  Journal of medicinal chemistry 20081113

• Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

  Schizophrenia research 20080801

• Clinical experiences and clinical trials.

  CNS spectrums 20080601

• A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.

  Journal of medicinal chemistry 20080508

• Acute dystonia induced by the combination of midodrine and perphenazine.

  Journal of neurology 20080501

• Did CATIE influence antipsychotic use?

  Psychiatric services (Washington, D.C.) 20080501

• Introduction to the CATIE special section.

  Psychiatric services (Washington, D.C.) 20080501

• What CATIE found: results from the schizophrenia trial.

  Psychiatric services (Washington, D.C.) 20080501

• Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

  The journal of behavioral health services & research 20080401

• The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

  Schizophrenia research 20080301

• Metoclopramide, an increasingly recognized cause of tardive dyskinesia.

  Journal of clinical pharmacology 20080301

• A somatic type delusional disorder secondary to peripheral neuropathy: a case report.

  Psychiatria Danubina 20080301

• Treatment of idiopathic recurrent priapism with fluoxetine and low dose Perphenazine.

  JPMA. The Journal of the Pakistan Medical Association 20080301

• Discontinuation of lithium augmentation in geriatric patients with unipolar depression: a systematic review.

  Canadian journal of psychiatry. Revue canadienne de psychiatrie 20080201

• Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

  Biological psychiatry 20080101

• Clinical characteristics and psychopathological profile of patients with vulvodynia: an observational and descriptive study.

  Dermatology (Basel, Switzerland) 20080101

• [Consumption of inappropriate psychotropic drugs in residential homes for the elderly: comparative study between 2001 and 2006].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20080101

• Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.

  Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists 20071201

• Aripiprazole and perphenazine: no difference.

  The Journal of clinical psychiatry 20071101

• CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.

  Pharmacogenetics and genomics 20071101

• Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: 'I don't see 'em!'.

  Journal of psychiatric practice 20070901

• Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.

  Schizophrenia research 20070701

• HPLC quantification of perphenazine in sheep plasma: application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070701

• Long-acting neuroleptics used in wildlife management do not impair thermoregulation or physical activity in goats (Capra hircus).

  Comparative biochemistry and physiology. Part A, Molecular & integrative physiology 20070601

• Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

  Archives of general psychiatry 20070601

• CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.

  Pharmacogenetics and genomics 20070501

• Permanent lithium-induced cerebellar toxicity: three cases and review of literature.

  Movement disorders : official journal of the Movement Disorder Society 20070315

• Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.

  Psychopharmacology 20070301

• Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

  The American journal of psychiatry 20070301

• Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

  The American journal of psychiatry 20070301

• Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.

  The Journal of clinical psychiatry 20070201

• [Antipsychotics--clever choices].

  Lakartidningen 20070201

• Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population.

  International clinical psychopharmacology 20070101

• Nerve growth factor mRNA expression in the regenerating antler tip of red deer (Cervus elaphus).

  PloS one 20070101

• Routine multimodal antiemesis including low-dose perphenazine in an ambulatory surgery unit of a university hospital: a 10-year history. Supplement to: Eliminating postoperative nausea and vomiting in outpatient surgery with multimodal strategies including low doses of nonsedating, off-patent antiemetics: is 'zero tolerance' achievable?

  TheScientificWorldJournal 20070101

• [Neuroleptic treatment and neurological soft signs in schizophrenic patients].

  Therapie 20070101

• Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

  The American journal of psychiatry 20061201

• Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia.

  International clinical psychopharmacology 20060901

• [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].

  No to shinkei = Brain and nerve 20060601

• Selecting antipsychotics in schizophrenia: lessons from CATIE.

  Journal of psychopharmacology (Oxford, England) 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Antipsychotic drugs and schizophrenia.

  The New England journal of medicine 20060119

• Antipsychotic drugs and schizophrenia.

  The New England journal of medicine 20060119

• Interpreting the results of the CATIE study.

  Psychiatric services (Washington, D.C.) 20060101

• Interpreting the results of the CATIE study.

  Psychiatric services (Washington, D.C.) 20060101

• Interpreting the results of the CATIE study.

  Psychiatric services (Washington, D.C.) 20060101

• In vitro phototoxicity of phenothiazines: involvement of stable UVA photolysis products formed in aqueous medium.

  Chemical research in toxicology 20060101

• Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.

  BMC psychiatry 20060101

• The CATIE schizophrenia effectiveness trial.

  Schizophrenia research 20051201

• Stability and characterization of perphenazine aerosols generated using the capillary aerosol generator.

  International journal of pharmaceutics 20051013

• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  The New England journal of medicine 20050922

• PASS assisted search and evaluation of some azetidin-2-ones as C.N.S. active agents.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20050803

• Depot perphenazine decanoate and enanthate for schizophrenia.

  The Cochrane database of systematic reviews 20050720

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• [Differentiation-inducing effects of perphenazine on K562 leukemia cells].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20050601

• Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.

  Psychopharmacology 20050501

• Mitochondria and plasma membrane as targets of UVA-induced toxicity of neuroleptic drugs fluphenazine, perphenazine and thioridazine.

  The international journal of biochemistry & cell biology 20050401

• Effect of anionic additive type on ion pair formation constants of basic pharmaceuticals.

  Journal of chromatography. A 20050401

• Kinetic spectrophotometric method for determination of perphenazine based on monitoring the oxidation intermediate by applying a stopped-flow technique.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20050301

• Application of two chemometric methods for the determination of imipramine, amitriptyline and perphenazine in content uniformity and drug dissolution studies.

  Journal of pharmaceutical and biomedical analysis 20050223

• Perphenazine for schizophrenia.

  The Cochrane database of systematic reviews 20050125

• Antiemetics in outpatient regional anesthesia for invasive orthopedic surgery.

  International anesthesiology clinics 20050101

• Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.

  Nordic journal of psychiatry 20050101

• Preliminary studies on phenothiazine-mediated reversal of multidrug resistance in mouse lymphoma and COLO 320 cells.

  In vivo (Athens, Greece) 20050101

• Comparison of the effect of the R2 phenothiazine ring substituent on fluphenazine and perphenazine interactions with cyclodextrins.

  Acta poloniae pharmaceutica 20050101

• A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.

  Psychopharmacology 20040901

• Nausea and vomiting after outpatient ACL reconstruction with regional anesthesia: are lumbar plexus blocks a risk factor?

  Journal of clinical anesthesia 20040601

• Photo-distributed neutrophilic drug eruption and adult respiratory distress syndrome associated with antidepressant therapy.

  Journal of cutaneous pathology 20040201

• An unexpected increase of troponin I after perphenazine depot injection.

  The Annals of pharmacotherapy 20040201

• Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients.

  The American journal of psychiatry 20040101

• Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.

  BMC psychiatry 20040101

• Induction of the rabbit syndrome following coadministration of paroxetine, perphenazine, and amitriptyline.

  Clinical neuropharmacology 20040101

• Schizophrenia, VI: Treatments.

  The American journal of psychiatry 20031001

• Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).

  Journal of medicinal chemistry 20030703

• Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.

  Pharmacology 20030601

• Photosensitization of DNA strand breaks by three phenothiazine derivatives.

  Chemical research in toxicology 20030501

• How long should patients with psychotic depression stay on the antipsychotic medication?

  The Journal of clinical psychiatry 20030401

• H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20030301

• Phenothiazine radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase: enzyme protection by radical scavengers.

  Free radical research 20030301

• New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.

  Journal of medicinal chemistry 20030102

• Drug-induced toxic myocarditis.

  Texas Heart Institute journal 20030101

• [Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial].

  Psychiatria polska 20030101

• Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.

  Psychopharmacology bulletin 20030101

• Simultaneous dissolution profiles of two drugs, sulfadiazine-trimethoprim and amitriptyline-perphenazine, in solid oral dosage forms by a FIA manifold provided with a single spectrophotometric detector.

  Journal of pharmaceutical and biomedical analysis 20021015

• Hydrophobia as a rare presentation of Cotard's syndrome: a case report.

  Acta psychiatrica Scandinavica 20020801

• Role of adenosine in drug-induced catatonia in mice.

  Indian journal of experimental biology 20020801

• [Simple preparation and evaluations of amide-octyl-bonded phase].

  Se pu = Chinese journal of chromatography 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Quantification of perphenazine in eurasian otter (Lutra lutra lutra) urine samples by gas chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020325

• Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.

  The American journal of psychiatry 20020301

• Extractive-spectrophotometric determination of some phenothiazines with dipicrylamine and picric acid.

  Journal of pharmaceutical and biomedical analysis 20020101

• Simultaneous determination of promethazine, chlorpromazine, and perphenazine by multivariate calibration methods and derivative spectrophotometry.

  Journal of AOAC International 20020101

• Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients.

  Proceedings of the Western Pharmacology Society 20020101

• Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.

  Cellular and molecular neurobiology 20011201

• Persistent changes in gene expression induced by estrogen and progesterone in the rat mammary gland.

  Molecular endocrinology (Baltimore, Md.) 20011101

• Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations.

  The Journal of nervous and mental disease 20011101

• Agranulocytosis and neutropenia with typical and atypical neuroleptics.

  The American journal of psychiatry 20011001

• Effects of ADP on different inhibitory properties of brain glutamate dehydrogenase isoproteins by perphenazine.

  Biochimie 20010901

• Evaluation of long-term sedation in cheetah (Acinonyx jubatus) with perphenazine enanthate and zuclopenthixol acetate.

  Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians 20010901

• Antipsychotic radioreceptor assay: a modification identifying selective receptor effects.

  Therapeutic drug monitoring 20010801

• Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.

  European journal of clinical pharmacology 20010701

• Noninvasive monitoring of adrenocortical activity in roe deer (Capreolus capreolus) by measurement of fecal cortisol metabolites.

  General and comparative endocrinology 20010701

• Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses.

  Journal of clinical psychopharmacology 20010401

• Therapeutic drug monitoring of haloperidol, perphenazine, and zuclopenthixol in serum by a fully automated sequential solid phase extraction followed by high-performance liquid chromatography.

  Therapeutic drug monitoring 20010401

• Fluvoxamine for psychosis in Alzheimer's disease.

  The Journal of nervous and mental disease 20010201

• The changes of biological markers and treatment efficacy in schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20010201

• Exacerbation of psychosis by phenylpropanolamine.

  The American journal of psychiatry 20000601

• [Diabetes mellitus after treatment with clozapine].

  Nederlands tijdschrift voor geneeskunde 20000226

• Perphenazine-induced hiccups.

  Pharmacopsychiatry 19990301

• Acquired aplastic anemia secondary to perphenazine.

  The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 19990101

• Olanzapine use in women with antipsychotic-induced hyperprolactinemia.

  The American journal of psychiatry 19981001

• Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.

  Biological psychiatry 19971201

• Induction of mania by risperidone resistant to mood stabilizers.

  Journal of clinical psychopharmacology 19970201

• Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.

  Psychopharmacology 19960301

• BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats.

  Journal of neural transmission (Vienna, Austria : 1996) 19960101

• The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.

  Anesthesia and analgesia 19950701

• Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.

  The Journal of pharmacology and experimental therapeutics 19940301

• Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.

  Acta psychiatrica Scandinavica 19931201

• D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.

  Psychopharmacology 19920101

• Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients.

  Pharmacopsychiatry 19910701

• The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.

  The Journal of clinical psychiatry 19900801

• Neurologic approach to drug-induced movement disorders: a study of 125 patients.

  Southern medical journal 19900501

• Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.

  Pharmacopsychiatry 19870701

• Neuroleptic malignant syndrome during perphenazine treatment.

  Pharmacology & toxicology 19870301

• L-tryptophan in drug-induced movement disorders with insomnia.

  The New England journal of medicine 19860508

• Tourette-like syndrome following low dose short-term neuroleptic treatment.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 19860501

• A case of progressive hemichorea responsive to high-dose reserpine.

  The Journal of clinical psychiatry 19860301

• Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.

  Psychopharmacology 19860101

• GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats.

  Archives internationales de pharmacodynamie et de therapie 19851201

• Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain.

  Naunyn-Schmiedeberg's archives of pharmacology 19850401

• Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.

  Proceedings of the National Academy of Sciences of the United States of America 19840901

• Unique sensitivity of Hb Zürich to oxidative injury by phenazopyridine: reversal of the effects by elevating carboxyhemoglobin levels in vivo and in vitro.

  American journal of hematology 19830601

• Cerebellar syndrome following neuroleptic induced heat stroke.

  Journal of neurology, neurosurgery, and psychiatry 19830201

• Capgras phenomenon, delirium, and transient hepatic dysfunction.

  Hospital & community psychiatry 19820501

• Dose-response relationships of perphenazine in the treatment of acute psychoses.

  Psychopharmacology 19820101

• Prolactin and the small intestine. Effect of hyperprolactinaemia on mucosal structure in the rat.

  Gut 19810701

• Actions of clonidine on convulsions and behaviour.

  Archives internationales de pharmacodynamie et de therapie 19810701

• Tricyclic antidepressants and alcoholic blackouts.

  The Journal of nervous and mental disease 19810601

• Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.

  Psychopharmacology 19810101

• Pituitary sensitivity to LHRH in hyperprolactinemia induced by perphenazine and renal pituitary transplants in female rats.

  Biology of reproduction 19800401

• Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment.

  The British journal of psychiatry : the journal of mental science 19791101

• Electrophysiologic studies of perphenazine and protriptyline in a patient with psychotropic drug-induced ventricular fibrillation.

  The American journal of medicine 19790801

• Seven cases of somnambulism induced by drugs.

  The American journal of psychiatry 19790701

• Metoclopramide and dystonic reactions in Sardinians.

  Lancet (London, England) 19790623

• Toxic psychosis with cimetidine.

  The American journal of psychiatry 19790501

• Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule.

  Canadian Medical Association journal 19781007

• [Acute dystonia in children. 2 cases caused by perphenazine (Trilafon)].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 19780310

• Effects and side-effects of bromperidol in comparison with other antipsychotic drugs.

  Acta psychiatrica Belgica 19780101

• Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.

  Lancet (London, England) 19770312

• Asymptomatic idiopathic syndrome of prolonged Q-T interval in a 45-year-old woman. Ventricular tachyarrhythmias precipitated by hypokalemia and therapy with amitriptyline and prephenazine.

  Chest 19770201

• Tetany, tetanus or drug reaction? A case report.

  British journal of anaesthesia 19760701

• High-dosage and versatile drug therapy with treatment-resistant psychotic patients.

  Hospital & community psychiatry 19760101

• [Psychometric effects of perphenacine below the 'neuroleptic threshold' (author's transl)].

  Pharmakopsychiatrie, Neuro-Psychopharmakologie 19751201

• Letter: Side-effects of perphenazine.

  Lancet (London, England) 19750621

• Drug-induced dystonia.

  The American journal of psychiatry 19750501

• Tardive dyskinesia treated with pimozide.

  Journal of the neurological sciences 19750401

• Tissue metabolites of trifluorperazine, fluphenazine, prochlorperazine, and perphenazine. Kinetics in chronic treatment.

  Drug metabolism and disposition: the biological fate of chemicals 19750101

• Reversal of delirium induced by tricyclic antidepressant drugs with physostigmine.

  The American journal of psychiatry 19741101

• Piritramide and pethidine. A comparison of their use as supplements in general anaesthesia.

  Anaesthesia 19741101

• The mechanism of the potentiating effect of antidepressant drugs on the protective influenc oe of diphenhydramine in experimental catatonia. The role of histamine.

  Pharmacology 19740101

• Idiosyncratic responses to phenothiazines.

  British medical journal 19720122

• A review of clinical studies with combinations of fluphenazine and nortriptyline.

  Current medical research and opinion 19720101

• Increased sensitivity to neuroleptics in rats with lesions of the central nervous system.

  Psychopharmacologia 19720101

• Sudden death in phenothiazine therapy. (A clinicopathologic study of 12 cases).

  The Psychiatric quarterly 19700101

• Iatrogenic epilepsy due to antidepressant drugs.

  British medical journal 19691011

• Dystonic reaction to perphenazine.

  Lancet (London, England) 19690809

• Perphenazine dystonia presenting as recurrent dislocation of the jaw.

  The Journal of laryngology and otology 19690101

• Phenothiazines and diabetes in hospitalized women.

  The American journal of psychiatry 19680101

• Oculogyric crises due to phenothiazines.

  British medical journal 19670722

• Side-effects of phenothiazines.

  British medical journal 19670401

• Phenothiazines in early labour.

  British medical journal 19670211

• The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.

  The Psychiatric quarterly 19670101

• Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients.

  Clinical pharmacology and therapeutics 19670101

• Drug-induced extrapyramidal symptoms: their incidence and treatment.

  The American journal of psychiatry 19670101

• A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.

  The British journal of psychiatry : the journal of mental science 19660601

• The effect of SA 97, perphenazine, and hydroxyzine on epinephrine-induced cardiac arrhythmias during methoxyflurane anaesthesia in dogs.

  Canadian Anaesthetists' Society journal 19620101

• The effect of perphenazine on epinephrine-induced cardiac arrhythmias in dogs. II. Anaesthesia with cyclopropane, chloroform, and trichlorethylene.

  Canadian Anaesthetists' Society journal 19590701